Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation
about
sameAs
Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challengesRole of the immunogenic and tolerogenic subsets of dendritic cells in multiple sclerosisSuccessful treatment of steroid-refractory immune thrombocytopenia with alemtuzumab.Human peripheral blood mononuclear cells exhibit heterogeneous CD52 expression levels and show differential sensitivity to alemtuzumab mediated cytolysis.Challenges in pediatric renal transplantationFludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes.Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression.Anti-IL6-receptor-alpha (tocilizumab) does not inhibit human monocyte-derived dendritic cell maturation or alloreactive T-cell responses.NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic maCord blood in regenerative medicine: do we need immune suppression?Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: current perspectives.Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity.The fate of human Langerhans cells in hematopoietic stem cell transplantationDendritic cells in allogeneic hematopoietic stem cell transplantation.Regulatory dendritic cell therapy in organ transplantation.Update on the therapy of highly aggressive non-Hodgkin's lymphoma.Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease.Alemtuzumab induction in pediatric kidney transplantation.Alemtuzumab (Campath-1H) in the treatment of chronic lymphocytic leukemia.Cancer vaccines for established cancer: how to make them better?Allogeneic immunotherapy to optimize the graft-versus-tumor effect: concepts and controversies.Treatment of graft-versus-host disease with monoclonal antibodies and related fusion proteins.Multiple sclerosis therapeutic pipeline: opportunities and challenges.Immune mechanisms underlying the beneficial effects of autologous hematopoietic stem cell transplantation in multiple sclerosis.Induction therapy in renal transplant recipients: how convincing is the current evidence?Disease-modifying treatments for progressive multiple sclerosis.Recollective homeostasis and the immune consequences of peritransplant depletional induction therapy.Alemtuzumab in multiple sclerosis: an update.The immunological function of CD52 and its targeting in organ transplantation.Immune regulation by CD52-expressing CD4 T cells.Eight-year follow-up in pediatric living donor kidney recipients receiving alemtuzumab induction.Alemtuzumab-induced elimination of HIV-1-infected immune cells.Alemtuzumab based reduced intensity transplantation for pediatric severe aplastic anemia.Alemtuzumab in allogeneic hematopoetic stem cell transplantation.The role of antigen-presenting cells in triggering graft-versus-host disease and graft-versus-leukemia.Alemtuzumab with corticosteroid minimization for pediatric deceased donor renal transplantation: a seven-yr experience.Low-dose alemtuzumab (Campath) in myeloablative allogeneic stem cell transplantation for CD52-positive malignancies: decreased incidence of acute graft-versus-host-disease with unique pharmacokinetics.A novel reduced-intensity stem cell transplant regimen for nonmalignant disorders.Intensive graft-versus-host disease prophylaxis is required after unrelated-donor nonmyeloablative stem cell transplantation.CD4+ CD25+ FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H.
P2860
Q26995399-0D2CD380-E909-47B5-AE00-77E282D5D0FFQ28082878-953BCDB1-CEE1-4DAE-A292-F1D0A185FB31Q33438455-CF594081-BA30-43E2-8915-F6AECFEC33EBQ34326110-4EC8D82E-B0D0-49DA-BCB3-81EE0FD4D501Q34761336-E2D4A638-3105-4C14-A5C2-0B235A80F8A5Q35142616-D06C9906-2D11-46AD-9485-1395FA3B9ED8Q35399334-7604B1E9-6945-4EB9-88C6-E414D12BBE37Q35553632-3CEB457D-DDF8-45EF-9949-4916F3A710CBQ35605318-DD6D976E-D632-4364-8B2A-F68A068384B1Q35633105-68DB5F38-4B03-439F-A8A8-BCF7AAE5F234Q35690761-FD1E83B9-A5C4-45E9-89B7-17E5F28A4330Q36014986-3AC9AEDC-2375-4461-BFB8-CDE5241F3F64Q36227929-ED67DB6F-55BB-49A1-8BC2-48B1A50A82FCQ36272587-709E85AF-DF85-46A5-8390-932191375646Q36501663-6AD4A7D9-0053-47F2-BF4A-2948FDF68BAAQ36521840-AFF66C7D-7968-4B44-AF41-D194CC37D859Q36813127-C7A660ED-CF57-483F-A360-6EC1C21C6337Q36818003-2F9C52CD-7951-477A-AA7C-B84DD43E64D3Q36832113-1902E42E-633B-41FE-BBD1-57DABA2434A0Q37118174-02EC1B9F-80B3-4E4C-92CE-F5976D89882EQ37810098-BAAEA285-30D1-4918-B9BC-650BBBD7F753Q37810286-14854DFF-9B92-43B0-A811-43B7AA45F94DQ37855722-C52E87A9-0918-4F01-A1A6-8C3B2CEB83BEQ37929621-5CB3F5B2-385B-47ED-8A05-4F6F467BBAC1Q37996078-DB11A6BB-1848-46FD-8E8C-310A237E6571Q38142030-DB0DE0BB-7DB9-4203-AE83-203242EF9807Q38187176-EA057AE5-3820-487E-BC10-762ADD2FD1BDQ38536770-75334853-7F9F-4C0F-B127-1C44802F389CQ38747419-D57780B9-853E-4CC8-BBD1-E2E6377B3239Q39025968-FECF9E15-602D-4E38-B757-777E600589FEQ39363717-F25F48DF-51A7-4488-86D3-81E4F19B6EBDQ40591737-1C5B0B15-A284-4EDD-A9AC-FA8F7B5A4C07Q41441009-E840C78C-CAB2-4CAE-A50A-6CC48E5D7A95Q42149544-2335E7C8-34FF-41E6-927F-C9C93375D8A9Q42151172-A3FD0C8E-7C75-4D05-95A2-7D7EC564417CQ42226145-1BD79016-A3EB-41B0-9C29-A0C0B09EB1A4Q44750591-803EDA80-7FCE-45EE-B6A3-169093E86A92Q45183631-6F992431-6F40-4A65-8AF6-E810527D6931Q46375783-4FACF861-601A-46A0-9538-619016975E70Q46763767-D99D740F-194A-472B-8967-A553F94C110F
P2860
Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Differential CD52 expression b ...... nteractions in transplantation
@ast
Differential CD52 expression b ...... nteractions in transplantation
@en
Differential CD52 expression b ...... nteractions in transplantation
@nl
type
label
Differential CD52 expression b ...... nteractions in transplantation
@ast
Differential CD52 expression b ...... nteractions in transplantation
@en
Differential CD52 expression b ...... nteractions in transplantation
@nl
prefLabel
Differential CD52 expression b ...... nteractions in transplantation
@ast
Differential CD52 expression b ...... nteractions in transplantation
@en
Differential CD52 expression b ...... nteractions in transplantation
@nl
P2093
P1433
P1476
Differential CD52 expression b ...... nteractions in transplantation
@en
P2093
Glenn Heller
Gudrun Ratzinger
James W Young
Klaus J Busam
P304
P356
10.1182/BLOOD-2002-04-1093
P407
P577
2003-02-15T00:00:00Z